vs
Side-by-side financial comparison of Aeluma, Inc. (ALMU) and RELMADA THERAPEUTICS, INC. (RLMD). Click either name above to swap in a different company.
Aeluma, Inc. is the larger business by last-quarter revenue ($1.3M vs $1.3M, roughly 1.0× RELMADA THERAPEUTICS, INC.). On growth, RELMADA THERAPEUTICS, INC. posted the faster year-over-year revenue change (13.0% vs -21.1%).
Aeluma, Inc. is a U.S.-headquartered technology firm focused on the design, development, and production of high-performance optoelectronic components and semiconductor products. Its core offerings include photonic sensors and laser diodes, serving the LiDAR, 5G/6G communication, industrial sensing, and automotive markets across North America and the Asia-Pacific region.
Relmada Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing novel therapies for central nervous system disorders. Its lead product candidate targets treatment-resistant depression, with ongoing clinical trials to address unmet medical needs in its primary markets of North America and Europe.
ALMU vs RLMD — Head-to-Head
Income Statement — Q2 FY2026 vs Q4 FY2023
| Metric | | |
|---|---|---|
| Revenue | $1.3M | $1.3M |
| Net Profit | $-1.9M | — |
| Gross Margin | 27.8% | — |
| Operating Margin | -163.6% | -2130.6% |
| Net Margin | -145.7% | — |
| Revenue YoY | -21.1% | 13.0% |
| Net Profit YoY | 36.0% | — |
| EPS (diluted) | $-0.11 | $-0.84 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $1.3M | — | ||
| Q3 25 | $1.4M | — | ||
| Q4 23 | — | $1.3M | ||
| Q3 23 | — | $1.3M | ||
| Q2 23 | — | $1.4M | ||
| Q1 23 | — | $1.2M | ||
| Q4 22 | — | $1.1M | ||
| Q3 22 | — | $827.6K |
| Q4 25 | $-1.9M | — | ||
| Q3 25 | $-1.5M | — | ||
| Q4 23 | — | — | ||
| Q3 23 | — | $-22.0M | ||
| Q2 23 | — | $-25.3M | ||
| Q1 23 | — | $-26.3M | ||
| Q4 22 | — | $-37.9M | ||
| Q3 22 | — | $-39.4M |
| Q4 25 | 27.8% | — | ||
| Q3 25 | 49.4% | — | ||
| Q4 23 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — | ||
| Q1 23 | — | — | ||
| Q4 22 | — | — | ||
| Q3 22 | — | — |
| Q4 25 | -163.6% | — | ||
| Q3 25 | -116.1% | — | ||
| Q4 23 | — | -2130.6% | ||
| Q3 23 | — | -1717.3% | ||
| Q2 23 | — | -1908.9% | ||
| Q1 23 | — | -2331.3% | ||
| Q4 22 | — | -3472.5% | ||
| Q3 22 | — | -4680.6% |
| Q4 25 | -145.7% | — | ||
| Q3 25 | -107.8% | — | ||
| Q4 23 | — | — | ||
| Q3 23 | — | -1665.0% | ||
| Q2 23 | — | -1855.9% | ||
| Q1 23 | — | -2179.6% | ||
| Q4 22 | — | -3404.5% | ||
| Q3 22 | — | -4762.9% |
| Q4 25 | $-0.11 | — | ||
| Q3 25 | $-0.09 | — | ||
| Q4 23 | — | $-0.84 | ||
| Q3 23 | — | $-0.73 | ||
| Q2 23 | — | $-0.84 | ||
| Q1 23 | — | $-0.87 | ||
| Q4 22 | — | — | ||
| Q3 22 | — | $-1.31 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $38.6M | $96.3M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $40.8M | $85.4M |
| Total Assets | $42.6M | $97.6M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $38.6M | — | ||
| Q3 25 | $25.9M | — | ||
| Q4 23 | — | $96.3M | ||
| Q3 23 | — | $106.3M | ||
| Q2 23 | — | $118.5M | ||
| Q1 23 | — | $132.4M | ||
| Q4 22 | — | $148.3M | ||
| Q3 22 | — | $141.6M |
| Q4 25 | $40.8M | — | ||
| Q3 25 | $40.9M | — | ||
| Q4 23 | — | $85.4M | ||
| Q3 23 | — | $100.7M | ||
| Q2 23 | — | $111.3M | ||
| Q1 23 | — | $125.5M | ||
| Q4 22 | — | $140.4M | ||
| Q3 22 | — | $166.3M |
| Q4 25 | $42.6M | — | ||
| Q3 25 | $42.7M | — | ||
| Q4 23 | — | $97.6M | ||
| Q3 23 | — | $109.1M | ||
| Q2 23 | — | $122.0M | ||
| Q1 23 | — | $135.6M | ||
| Q4 22 | — | $152.9M | ||
| Q3 22 | — | $187.1M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-251.0K | $-10.2M |
| Free Cash FlowOCF − Capex | $-282.0K | — |
| FCF MarginFCF / Revenue | -22.2% | — |
| Capex IntensityCapex / Revenue | 2.4% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-251.0K | — | ||
| Q3 25 | $-815.0K | — | ||
| Q4 23 | — | $-10.2M | ||
| Q3 23 | — | $-11.6M | ||
| Q2 23 | — | $-13.3M | ||
| Q1 23 | — | $-16.5M | ||
| Q4 22 | — | $-35.9M | ||
| Q3 22 | — | $-26.9M |
| Q4 25 | $-282.0K | — | ||
| Q3 25 | $-1.0M | — | ||
| Q4 23 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — | ||
| Q1 23 | — | — | ||
| Q4 22 | — | — | ||
| Q3 22 | — | — |
| Q4 25 | -22.2% | — | ||
| Q3 25 | -74.0% | — | ||
| Q4 23 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — | ||
| Q1 23 | — | — | ||
| Q4 22 | — | — | ||
| Q3 22 | — | — |
| Q4 25 | 2.4% | — | ||
| Q3 25 | 15.2% | — | ||
| Q4 23 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — | ||
| Q1 23 | — | — | ||
| Q4 22 | — | — | ||
| Q3 22 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
